Υγεία

Accelerated Approval of Elevidys (SRP-9001) for Children with DMD

Η αναφορά απευθύνεται σε
Europäische Arzneimittel-Agentur (EMA)
30.404 Υποστηρικτικό

Η συλλογή ολοκληρώθηκε

30.404 Υποστηρικτικό

Η συλλογή ολοκληρώθηκε

  1. Ξεκίνησε Ιουνίου 2023
  2. Η συλλογή ολοκληρώθηκε
  3. Προετοιμασία υποβολής
  4. Διαλόγο με τον παραλήπτη
  5. Απόφαση

Lady's and Gentlemen

As the undersigned of this petition, we would like to speak out in favor of Elevidys (SRP-9001) from Sarepta Therapeutics / Roche being approved quickly in Europe for children with Duchenne muscular dystrophy (DMD) who are able to walk. We believe this approval is urgently needed because every day counts for patients and the fastest possible treatment can mean a significant improvement in the quality of life for patients with DMD.

Αιτιολόγηση

DMD is an inherited disease that can lead to a gradual deterioration in muscle function and ultimately to respiratory and cardiac impairment. There is currently no cure for DMD, and existing therapies are primarily aimed at relieving the symptoms of the disease. However, SRP-9001 offers a promising avenue to target the disease.

In the most common form, Duchenne muscular dystrophy, the prognosis is serious. Those affected usually die at the age of 20 to 25 from the progressive deterioration of the heart and respiratory muscles.

SRP-9001 has just been approved in the US and has shown significant improvements in patients with DMD in multiple studies. The rapid approval of SRP-9001 in Europe could give many European patients the same opportunity for an improved quality of life.

Therefore, we urge you to advocate for rapid approval of Sarepta Therapeutics' SRP-9001 in Europe for Duchenne muscular dystrophy. Every day matters for the patients with DMD and we believe that SRP-9001 represents a very good treatment option.

More information about SRP-9001

Σας ευχαριστούμε για την υποστήριξή σας , Kai Andre-Lüchtefeld από Bad Laer
Ερώτηση προς τον εκκινητή

Σύνδεσμος προς την αναφορά

Εικόνα με κωδικό QR

Δελτίο αποκοπής με κωδικό QR

κατεβάσετε (PDF)

Αυτή η αναφορά έχει μεταφραστεί στις ακόλουθες γλώσσες

Νέα

  • Support for the gene therapy petition

    Dear Sir or Madam

    I hope this email reaches you in good health and good spirits. I am writing to you on behalf of our petition group, which is campaigning for rapid approval of Sarepta Therapeutics SRP-9001 (Elevidys) gene therapy in Germany.

    As you may know, this gene therapy was approved in the USA almost six months ago. Since then, we have received more and more positive feedback from various publicly accessible forums supporting patients with Duchenne muscular dystrophy (DMD) about the effect of the gene therapy.

    Some parents report that after 8 weeks of gene therapy administration, there are no more signs of the "Growers' sign", which is typical for boys with DMD and describes the difficulty... παρακάτω

  • Changes to the petition

    στον/-ην/-ο 02.11.2023

Συζήτηση

Bolni otroci si zaslužijo vsa možna zdravljenja. Denar je tu najmanj pomemben problem.

Ακόμα κανένα επιχείρημα κατά.

Αυτή η αναφορά έχει μεταφραστεί στις ακόλουθες γλώσσες

Βοήθεια για την ενίσχυση της συμμετοχής των πολιτών. Θέλουμε, να ακούσουμε τα αιτήματα σας παραμένοντας ανεξάρτητοι.

Προωθήστε τώρα